Case Report

Growth Rate Analysis of an Untreated Glomus Vagale on MRI

Jeffrey Tzu-Yu Wang, Allen Yu-Yu Wang, Sheila Cheng, Lavier Gomes, and Melville Da Cruz

1Department of Radiology, Westmead Hospital, University of Sydney, Sydney, NSW 2145, Australia
2Department of Otolaryngology, Westmead Hospital, University of Sydney, Sydney, NSW 2145, Australia

Correspondence should be addressed to Jeffrey Tzu-Yu Wang; jeffwang0725@gmail.com

Received 19 November 2015; Accepted 22 February 2016

Copyright © 2016 Jeffrey Tzu-Yu Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paragangliomas are slow growing, hypervascular neuroendocrine tumors that develop in the extra-adrenal paraganglion tissues. Paraganglioma involving the vagus nerve ganglia is termed glomus vagale. The slow growth of head and neck paragangliomas especially in the absence of symptom may obviate the necessity for any active intervention, in which case, a “wait and scan” policy is implemented involving long-term clinical and radiologic follow-ups. We present a case of a 71-year-old female with an untreated left glomus vagale who underwent a conservative “wait and rescan” plan of management and the tumor was observed with 8 serial MRI scans over a period of 7.4 years. A growth rate analysis was conducted which demonstrated a slow growth. A literature review of radiologic studies examining the natural history of head and neck paragangliomas was also performed.

1. Introduction

Paragangliomas are slow growing, hypervascular neuroendocrine tumors that develop in the extra-adrenal paraganglion tissues. In the head and neck region they account for 0.6% of all tumors and are labeled by their anatomic site of origin: vagus nerve ganglia (glomus vagale), carotid body at the bifurcation of common carotid artery (carotid body tumor), jugular bulb (glomus jugulare), and tympanic plexus (glomus tympanicum). Approximately 80% of head and neck paragangliomas are either carotid body tumors or glomus jugulare [1].

The management options include surgical resection, conventional radiation therapy, stereotactic radiosurgery, permanent embolization, a combination of these modalities, and observation. Surgery is the only curative treatment but it may be complicated by significant postoperative morbidity particularly in larger tumors [1]. There has been a shift in the treatment paradigm to a more conservative approach. Improved knowledge, experience, and recognition of a low incidence of malignancy have allowed individualization of management [2]. The slow growth of these tumors, especially in the absence of symptom, may obviate the necessity for any active intervention, in which case, a “wait and scan” policy is implemented involving long-term clinical and radiologic follow-ups. The imaging modalities used in the radiologic follow-up are computed tomography (CT) or magnetic resonance imaging (MRI) [3].

In the existing literature, there have been four radiologic studies which have examined the natural history of head and neck paragangliomas [2, 4–6]. Further robust data concerning the growth of these tumors is required which will assist clinicians in treatment planning. In head and neck paragangliomas, tumor growth and surgical resection can lead to disabling loss of cranial nerve (CN) functions; therefore having an insight into the natural history is essential for the development of treatment strategies. In this paper we present a case of an untreated left glomus vagale who underwent 8 serial MRI scans over a period of 7.4 years, and the growth rate analysis of the tumor.

2. Case Presentation

A 71-year-old female presented with mild pharyngeal discomfort. Clinical examination revealed medial displacement of the left tonsil associated with transmitted pulsation of
the surrounding pharyngeal wall. No cranial nerve palsy was evident. MRI showed a well-defined mass in the left parapharyngeal space. $T_1$ weighted sequences demonstrated low signal intensity with multiple voids. On $T_2$ weighted sequences the mass was of high signal intensity and revealed extensive enhancement following administration of gadolinium. Radiologic features were consistent with glomus vagale.

In light of her minimally disabling symptoms and the tumor being located on the side of her only seeing eye, the patient underwent a conservative “wait and rescans” plan of management. The tumor was observed with 8 serial MRI scans over a period of 7.4 years since 2006. This allowed a linear regression model to estimate the growth rates of its maximum axial dimension, maximum axial area, and volume.

Tumor size measurement was acquired on both hard copies and electronic images of MRI using a standardized method (Figure 1). Dimensions were measured in 3 perpendicular axes. The largest dimensions in the anteroposterior ($X$) and mediolateral ($Y$) directions were measured on axial slices. If available, coronal or sagittal slices were utilized to measure the largest dimension in the craniocaudal direction ($Z$); otherwise it was estimated to be the product of slice thickness and number of slices in which the tumor could be identified. The maximum axial dimension was taken as $X$, which was the larger of the two dimensions on axial slice. Tumor was conceptualized to have an ellipsoid shape. The 3 perpendicular dimensions were used in the ellipsoid area and volume formulas to calculate the maximum axial area and volume of the tumor:

$$\text{Ellipsoid area (cm}^2\) = π\left(\frac{1}{2}\right)XY$$

$$\text{Ellipsoid volume (cm}^3\) = \left(\frac{4}{3}\right)π\left(\frac{1}{2}\right)XYZ.$$  

In order to standardize the measurement method on serial imaging, the baseline images were used for comparison to ensure that tumor dimensions were measured in the same orientation and on the same anatomical plane by identifying anatomical landmarks.

On serial MRI scans, the untreated glomus vagale demonstrated slow growth in a linear trend. No evidence of exponential growth was found. The maximum axial dimension revealed a growth rate of 0.68 mm/year (standard error 0.11 mm; $p = 0.001; R^2 = 87\%$), growing from 4.6 cm to 5.2 cm (13% growth) in a linear trend (Figure 2(a)). The maximum axial area illustrated a more stable trend with a growth rate of 0.04 cm$^2$/year and a minimal growth from 10.8 cm$^2$ to 11.0 cm$^2$ (2% growth) (Figure 2(b)). The volume demonstrated a growth rate of 1.6 cm$^3$/year growing from 32.5 cm$^3$ to 47.1 cm$^3$ (45% growth) in a linear trend (Figure 2(c)). Tumor doubling time was estimated to be 13.82 years using the following formula [1]:

$$T_d = (T_2 - T_1) \left[\frac{\log 2}{\log V_2 - \log V_1}\right].$$ 

where $T_d$ is tumor doubling time, $T_2$ is last imaging time, $T_1$ is first imaging time, $V_2$ is volume at $T_2$, and $V_1$ is volume at $T_1$.

3. Discussion

The current study has demonstrated slow growth of an untreated glomus vagale. Four prior radiologic studies examining the natural history of head and neck paragangliomas (Table 1) have also shown slow growth. Boedeker [11] described the factors that play an important role in the search for optimal therapy including size, classification, and site of the tumor, and age and general health of the patient, as well as associated CN deficits. The patient's psychological and social status, treatment preferences, and baseline quality of life also need to be taken into consideration [12]. It has gradually become accepted by many clinicians that conservative management can represent effective management strategy to stand next to surgical resection and is not merely a compromise therapy.
Figure 1: (a) The untreated left glomus vagale was considered to have an ellipsoid shape. The 3 perpendicular dimensions in the anteroposterior (X), mediolateral (Y), and craniocaudal (Z) directions were used to calculate the maximum axial area and volume. ((b)–(e)) Serial MRI scans (T2 fat saturation suppressed sequence) on axial slice performed in 2012 (b) and 15 months later (c), and on coronal slice performed in 2012 (d) and 15 months later (e), have demonstrated minimal change in tumor size over time. The maximum axial dimension was taken as X, which is the larger of the two dimensions on axial slice (X and Y).

reserved for those unfit for surgery. Due to the low risk of malignancy and slow growing nature of head and neck paragangliomas, it may be appropriate in selected cases to withhold any kind of invasive therapy. Observation by a “wait and scan” policy involving long-term clinical and radiologic follow-ups may be considered in asymptomatic cases [13–15]. It could also be the primary option for defining the growth pattern. However, provided the increasing life span, even slow growing tumors may progress in the long term and cause delayed and irreversible complications. Patients undergoing watchful waiting should be informed that many tumors continue to grow, and they may eventually require treatment [12]. By postponing surgery until CN impairment becomes evident or other vital structures are threatened,
**Figure 2:** Growth rates of the untreated left glomus vagale on serial MRI scans as estimated by linear regression model. (a) Maximum axial dimension demonstrates a growth rate of 0.68 mm/year in a linear trend. (b) Maximum axial area illustrates a stable trend, with a growth rate of 0.04 cm²/year. (c) Volume demonstrates a growth rate of 1.6 cm³/year in a linear trend.

CN function can frequently be preserved until later in the natural history, whereas performing surgery upon diagnosis can often lead to CN impairment earlier in the history of the disease [1].

The management of glomus vagale follows the same evolving trend as head and neck paragangliomas. The decision between surgery and watchful waiting is based on critical factors including the likely natural history, age of the patient, size and growth rate of the tumor, and associated CN deficits [16]. There has been an increasing trend for glomus vagale to be managed by a “wait and scan” policy. Our finding of a slow growing glomus vagale further supports this trend. Bradshaw and Jansen [17] noted a rise in the percentage of glomus vagale undergoing watchful waiting over the years. A conservative approach in a glomus vagale patient with functional larynx is crucial, as gradually developing vagus nerve palsy may undergo satisfactory compensation. On the other hand, surgery carries the risk of aspiration following sudden loss of vagal function.

The current report is the first study in the literature to analyze the growth of an untreated glomus vagale in depth using linear regression model. In head and neck paragangliomas, the natural history is one of the critical factors which influence treatment planning. By reporting a detailed growth rate analysis of a slow growing glomus vagale has allowed better understanding of its natural history. This result also adds to the existing literature allowing clinicians to more effectively counsel head and neck paraganglioma patients as to the benefits of a “wait and scan” policy.

**Disclosure**

This study was presented at the Combined Scientific Meeting for Royal Australian and New Zealand College of Radiologists, Melbourne, Australia, September 4, 2014, and the Australian Society of Otolaryngology Head and Neck Surgery Annual Scientific Meeting, Sydney, Australia, March 7, 2015.
Table 1: Literature review of radiologic studies investigating natural history of head and neck paragangliomas.

| Study                  | Number of cases | Tumor subsite | Average FU duration (years) | Imaging | Average growth rates in growing tumors | Tumor doubling time (yr) | Number of tumors with change in size |
|------------------------|-----------------|---------------|----------------------------|---------|----------------------------------------|--------------------------|-------------------------------------|
|                        |                 |               |                            |         | Average maximum axial dimension (mm/yr) |                          | Regression Stable Growth            |
|                        |                 |               |                            |         | Maximum axial area (cm²/yr)            |                          |                                     |
|                        |                 |               |                            |         | Volume (cm³/yr)                        |                          |                                     |
| Current study          | 1               | GV            | 7.5                        | MRI     | 0.68                                   | 0.04                     | 1.60                                |
| Carlson et al., 2015   | 12              | GJ            | 7.2                        | MRI     | 0.80                                   | NA                       | 0.44                                |
| Prasad et al., 2014    | 23              | GJ            | 5.1                        | MRI     | NA*                                    | NA                       | NA                                  |
| Langerman et al., 2012 | 47              | GV (19 cases) CBT (28 cases) | 5.0           | CT, MRI | 2.00                                   | 0.58                     | NA                                  |
| Jansen et al., 2000    | 48              | GJ (11 cases) CBT (20 cases) | 4.2           | CT, MRI | 0.83                                   | NA                       | NA*                                 |
| Mean                   | 26              | NA            | 5.8                        | NA      | 1.10                                   | 0.31                     | 1.00                                |

FU: follow-up, yr: year, GV: glomus vagale, MRE: magnetic resonance imaging, NA: not available, GJ: glomus jugulare, CBT: carotid body tumor, and CT: computed tomography.

* An exact average value was not available. Grow rates were <3.00 mm/year in 7 tumors and >3.00 mm/year in 1 tumor.

** Tumor volume was measured in this study; however the growth rate of the volume was not available.

*** This mean percentage does not include the current study which involves a single case of tumor.
Competing Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments
The authors wish to acknowledge Dr. Karen Byth, Ph.D., for the invaluable statistical advice and analysis. The authors also thank Castlereagh Imaging, Westmead (Sydney, Australia), for providing radiologic imaging.

References
[1] D. Destito, S. Bucolo, A. Florio, and C. Quattrocchi, "Management of head and neck paragangliomas: a series of 9 cases and review of the literature," Ear, Nose and Throat Journal, vol. 91, no. 8, pp. 366–375, 2012.
[2] A. Langerman, S. M. Athavale, S. V. Rangarajan, R. J. Sinard, and J. L. Netterville, "Natural history of cervical paragangliomas: outcomes of observation of 43 patients," Archives of Otolaryngology—Head and Neck Surgery, vol. 138, no. 4, pp. 341–345, 2012.
[3] P. K. Pellitteri, A. Rinaldo, D. Myssiorek et al., "Paragangliomas of the head and neck," Oral Oncology, vol. 40, no. 6, pp. 563–575, 2004.
[4] M. L. Carlson, A. D. Sweeney, G. B. Wanna, J. L. Netterville, and D. S. Haynes, "Natural history of glomus jugulare: a review of 16 tumors managed with primary observation," Otolaryngology—Head and Neck Surgery, vol. 152, no. 1, pp. 98–105, 2015.
[5] S. C. Prasad, H. A. Mimoune, F. D’Orazio et al., "The role of wait-and-scan and the efficacy of radiotherapy in the treatment of temporal bone paragangliomas," Otology and Neurotology, vol. 35, no. 5, pp. 922–931, 2014.
[6] J. C. Jansen, R. van den Berg, A. Kuiper, A. G. L. van der Mey, A. H. Zwinderman, and C. J. Cornelisse, "Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal," Cancer, vol. 88, no. 12, pp. 2811–2816, 2000.
[7] J. K. Varughese, C. N. Breivik, T. Wentzel-Larsen, and M. Lund-Johansen, "Growth of untreated vestibular schwannoma: a prospective study," Journal of Neurosurgery, vol. 116, no. 4, pp. 706–712, 2012.
[8] S. Charabi, "Acoustic neuroma/vestibular schwannoma in vivo and in vitro growth models. A clinical and experimental study," Acta Oto-Laryngologica Supplement, vol. 530, pp. 1–27, 1997.
[9] T. P. C. Martin, L. Senthil, S. V. Chavda, R. Walsh, and R. M. Irving, "A protocol for the conservative management of vestibular schwannomas," Otology and Neurotology, vol. 30, no. 3, pp. 381–385, 2009.
[10] E. Myrseth, P.-H. Pedersen, P. Möller, and M. Lund-Johansen, "Treatment of vestibular schwannomas. Why, when and how?" Acta Neurochirurgica, vol. 149, no. 7, pp. 647–660, 2007.
[11] C. C. Boedeker, "Paragangliomas and paraganglioma syndrome," GMS Current Topics in Otorhinolaryngology—Head and Neck Surgery, vol. 10, Article ID Doc03, 2011.
[12] D. Taieb, A. Kaliski, C. C. Boedeker et al., "Current approaches and recent developments in the management of head and neck paragangliomas," Endocrine Reviews, vol. 35, no. 5, pp. 795–819, 2014.
[13] M. S. Persky, A. Setton, Y. Niimi, J. Hartman, D. Frank, and A. Berenstein, "Combined endovascular and surgical treatment of head and neck paragangliomas—a team approach," Head and Neck, vol. 24, no. 5, pp. 423–431, 2002.
[14] A. Westerban, G. C. Hunter, I. Cintora et al., "Current trends in the detection and management of carotid body tumors," Journal of Vascular Surgery, vol. 28, no. 1, pp. 84–93, 1998.
[15] M. Makeiell, J. Thariat, E. Rey, and C.-A. Righini, "Treatment of cervical paragangliomas," European Annals of Otorhinolaryngology, Head and Neck Diseases, vol. 129, no. 6, pp. 308–314, 2012.
[16] E. Zanoletti and A. Mazzoni, "Vagal paraganglioma," Skull Base, vol. 16, no. 3, pp. 161–168, 2006.
[17] J. W. Bradshaw and J. C. Jansen, "Management of vagal paraganglioma: is operative resection really the best option?" Surgery, vol. 137, no. 2, pp. 225–228, 2005.